Opportunity Information: Apply for RFA MD 18 010
The Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42 - Clinical Trial Optional) opportunity, listed as RFA-MD-18-010, is a National Institutes of Health (NIH) funding announcement designed specifically for U.S. small businesses that want to translate research into practical, market-ready solutions that improve minority health and reduce health disparities. The program uses the Small Business Technology Transfer (STTR) mechanism, which is built around a formal partnership between a small business concern (SBC) and a nonprofit research institution. In plain terms, it is meant to help a small company and a research partner jointly develop a technology that can realistically be commercialized and adopted in the real world, rather than staying at the proof-of-concept stage.
The core goal of the announcement is to support the development of a product, process, or service that helps address documented health gaps affecting NIH-defined health disparity population groups. While the notice does not list every population group in the excerpt provided, the intent is clear: the proposed technology should target conditions and outcomes where disparities exist, and it should do so in a way that is not only scientifically sound but also practical for the communities most affected. NIH emphasizes that the technologies should be effective, affordable, and culturally acceptable, which is an important signal that reviewers will likely look beyond technical performance alone. They will care about whether the solution can be used and trusted by the intended population, whether it fits real-life constraints like cost and access, and whether it is designed in a way that respects language, norms, and lived experience.
This opportunity falls under the NIH grant category and is associated with CFDA number 93.307, indicating it is part of the NIH portfolio focused on minority health and health disparities. The activity uses the R41/R42 STTR phases: typically, R41 (Phase I) supports early feasibility work and prototype development, while R42 (Phase II) supports more advanced development such as refinement, validation, and preparation for commercialization. The announcement notes "Clinical Trial Optional," meaning applicants may propose a project that includes a clinical trial if it is appropriate for the technology and stage of development, but they are not required to do so. This flexibility matters because some technologies may need human testing to demonstrate impact, while others may be better suited to laboratory validation, simulation, usability studies, or implementation-focused work before moving into clinical trials.
Eligibility is limited to U.S. small business concerns as the primary applicants. Foreign institutions are explicitly not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply as components of the applicant organization. However, the announcement leaves room for "foreign components" as defined under the NIH Grants Policy Statement, which generally means certain discrete project elements may be conducted outside the U.S. if they are strongly justified and meet NIH policy requirements. Practically, most applicants should plan for the major work and leadership to be U.S.-based and should treat any international involvement as exceptional and tightly justified rather than routine.
From a competitiveness standpoint, the emphasis on commercialization is not just a buzzword. Applicants should be prepared to explain why the proposed technology has a real path to adoption: who will use it, who will pay for it, how it fits into existing care workflows or public health systems, what the regulatory or compliance pathway looks like (if relevant), and what makes it sustainable beyond the grant period. Because the target is minority health and disparity reduction, strong applications would typically show a clear connection between the technology and a specific disparity (for example, reduced access, lower screening rates, higher complication rates, or poorer treatment adherence) and then explain how the technology measurably improves outcomes in that context. Affordability and cultural acceptability are also practical design requirements, not afterthoughts, so applicants would generally be expected to show evidence of community input, user-centered design, language access planning, and consideration of the settings where the tool will actually be deployed (such as community clinics, rural practices, safety-net hospitals, schools, faith-based settings, or home use).
Administrative details in the source information indicate the opportunity was created on 2018-08-01 with an original closing date of 2019-04-01. The listing identifies NIH as the agency and "Health" as the funding activity category. Some fields like the award ceiling, expected awards, and the number of awards are not specified in the excerpt, so an applicant would normally confirm budget limits and other constraints in the full FOA text. Even without those specifics, the overall structure is clear: it is an NIH STTR grant opportunity intended to move technologies from research toward real-world products and services that can help close persistent gaps in health outcomes for disparity-affected populations in the United States.Apply for RFA MD 18 010
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.307.
- This funding opportunity was created on 2018-08-01.
- Applicants must submit their applications by 2019-04-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42 - Clinical Trial Optional) (RFA-MD-18-010)
What is RFA-MD-18-010?
RFA-MD-18-010 is a National Institutes of Health (NIH) funding opportunity for U.S. small businesses to develop and translate technologies aimed at improving minority health and reducing health disparities. It uses the STTR (Small Business Technology Transfer) mechanism, which requires a formal collaboration between a small business and a nonprofit research institution.
What is the main purpose of this funding opportunity?
The main purpose is to support development of a product, process, or service that addresses documented health gaps affecting NIH-defined health disparity population groups, with a strong focus on creating practical, market-ready solutions rather than stopping at proof-of-concept research.
Who is this opportunity intended for?
This opportunity is designed specifically for U.S. small business concerns (SBCs) that want to partner with a nonprofit research institution to develop a technology that can be commercialized and adopted in real-world settings.
What funding mechanism does this opportunity use?
The opportunity uses the Small Business Technology Transfer (STTR) mechanism under the R41/R42 activity codes.
What do the R41 and R42 phases generally support?
R41 (Phase I) typically supports early feasibility work and prototype development. R42 (Phase II) typically supports more advanced development work such as refinement, validation, and preparation for commercialization.
Are clinical trials required?
No. The announcement is labeled "Clinical Trial Optional," meaning a project may include a clinical trial if it makes sense for the technology and its development stage, but a clinical trial is not required.
What kinds of projects would be a good fit if they do not include a clinical trial?
Based on the information provided, non-trial projects could still be appropriate when the technology is better suited to laboratory validation, simulation, usability studies, or implementation-focused development work prior to moving into clinical trials.
What types of solutions are NIH looking for under this opportunity?
NIH is looking for technologies that can realistically be commercialized and adopted, including products, processes, or services that help reduce health disparities and improve minority health outcomes.
What are the key characteristics NIH emphasizes for the proposed technologies?
The notice emphasizes that technologies should be effective, affordable, and culturally acceptable. This suggests reviewers will likely consider real-world usability and adoption factors, not only technical performance.
What does "culturally acceptable" imply in the context of this opportunity?
It implies the technology should be designed in a way that communities can use and trust, taking into account factors like language access, norms, lived experience, and practical constraints related to access and cost.
How important is commercialization in this FOA?
Commercialization is a core emphasis. Applicants are expected to explain a plausible path to adoption, including who will use the technology, who will pay for it, how it fits into workflows or systems, and what makes it sustainable beyond the grant period.
What kinds of disparity-related needs should a strong project connect to?
A strong project would typically connect the technology to a specific disparity context, such as reduced access, lower screening rates, higher complication rates, or poorer treatment adherence, and explain how the technology would measurably improve outcomes.
What eligibility restrictions apply to foreign organizations?
Foreign institutions are explicitly not eligible to apply. Non-U.S. components of U.S. organizations are also not eligible to apply as components of the applicant organization.
Are any international activities allowed at all?
The announcement indicates that "foreign components" may be possible as defined under the NIH Grants Policy Statement, generally meaning discrete project elements outside the U.S. may be allowed if strongly justified and compliant with NIH policy requirements.
What does the STTR partnership requirement mean in practical terms?
It means the small business (as the primary applicant) must have a formal partnership with a nonprofit research institution, and the project is intended to leverage both the commercial translation capabilities of the small business and the research strengths of the partner institution.
What is the CFDA number associated with this opportunity?
The opportunity is associated with CFDA number 93.307, indicating it is part of the NIH portfolio focused on minority health and health disparities.
Which agency is offering this funding opportunity?
The funding opportunity is offered by the National Institutes of Health (NIH).
What is the funding activity category?
The listing identifies the funding activity category as Health.
When was this opportunity created and what was the original closing date?
The opportunity was created on 2018-08-01 and had an original closing date of 2019-04-01.
Are award amounts, award ceilings, or number of awards provided in the excerpt?
No. The excerpt indicates that fields such as award ceiling, expected awards, and number of awards are not specified, and applicants would normally confirm those details in the full funding opportunity announcement (FOA) text.
What kinds of real-world deployment settings does the description suggest applicants should consider?
The description suggests designing with real-world settings in mind, such as community clinics, rural practices, safety-net hospitals, schools, faith-based settings, or home use, and incorporating community input and user-centered design considerations.
Does the excerpt list every NIH-defined health disparity population group?
No. The excerpt notes that the notice does not list every population group in the provided text, but it clearly states that proposed technologies should target conditions and outcomes where disparities exist.
What does "translate research into practical, market-ready solutions" mean here?
It means the program is intended to help move beyond early research toward a solution that can be used in the real world, including development work that supports adoption, implementation, and commercialization.
Browse more opportunities from the same category: Health
Next opportunity: U.S. Mission to South Africa: Ambassadors Fund for Cultural Preservation
Previous opportunity: Preservation and Skills Develpment Internship
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA MD 18 010
Applicants also applied for:
Applicants who have applied for this opportunity (RFA MD 18 010) also looked into and applied for these:
| Funding Opportunity |
|---|
| Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) Apply for RFA MD 18 009 Funding Number: RFA MD 18 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Management of Asthma in Primary Care - Clinical Center (UG3/UH3 - Clinical Trial Required) Apply for RFA HL 19 005 Funding Number: RFA HL 19 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Management of Asthma in Primary Care - Bioinformatics Center (U24 - Clinical Trial Required - Infrastructure) Apply for RFA HL 19 006 Funding Number: RFA HL 19 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alzheimer Centers for Discovery of New Medicines (U54 Clinical Trial Not Allowed) Apply for RFA AG 19 010 Funding Number: RFA AG 19 010 Agency: National Institutes of Health Category: Health Funding Amount: $5,250,000 |
| 2019 YSEALI Regional Workshop: Partnership in Health – Community-based Prevention for Non-communicable Diseases and Mental Health Apply for PAS ID 18 003 Funding Number: PAS ID 18 003 Agency: U.S. Mission to Indonesia Category: Health Funding Amount: $250,000 |
| Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01 Clinical Trial Not Allowed) Apply for PAR 18 889 Funding Number: PAR 18 889 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project: Opportunity for Revision Requests for Active Cooperative Agreements (U01 Clinical Trial Not Allowed) Apply for PAR 18 890 Funding Number: PAR 18 890 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Neuroprotection (U01 Clinical Trial Not Allowed) Apply for RFA NS 18 033 Funding Number: RFA NS 18 033 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Extracellular RNA (exRNA) Communication Research: Improved Isolation and Analysis of exRNA-Carrier Subclasses (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA RM 18 027 Funding Number: RFA RM 18 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited competition: Data Management and Resource Repository (DMRR) on Extracellular RNA (U54 Clinical Trial Not Allowed) Apply for RFA RM 18 026 Funding Number: RFA RM 18 026 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Neuroprotection - Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA NS 18 034 Funding Number: RFA NS 18 034 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Advancing Extracellular RNA (exRNA) Communication Research: Towards Single Extracellular Vesicle (EV) Sorting, Isolation, and Analysis of Cargo (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA RM 18 028 Funding Number: RFA RM 18 028 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIMHD Minority Health and Health Disparities Research Training (MHRT) Program (T37) Apply for RFA MD 18 007 Funding Number: RFA MD 18 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed) Apply for PAR 18 894 Funding Number: PAR 18 894 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| CNS-Targeted Drug Delivery Strategies for HIV (R01 Clinical Trial Not Allowed) Apply for PAR 18 895 Funding Number: PAR 18 895 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Trial on Effects of Statins in Older Adults without Clinical Cardiovascular Disease (U19 Clinical Trial Required) Apply for RFA AG 19 020 Funding Number: RFA AG 19 020 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional) Apply for RFA MH 19 240 Funding Number: RFA MH 19 240 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (X02 Clinical Trial Not Allowed) Apply for PAR 18 899 Funding Number: PAR 18 899 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Adaptations to Simplify Existing Technologies for Manipulation and Analysis of Glycans (U01 Clinical Trial Not Allowed) Apply for RFA RM 18 037 Funding Number: RFA RM 18 037 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases (X02 Clinical Trial Not Allowed) Apply for PAR 18 900 Funding Number: PAR 18 900 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA MD 18 010", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.